Phase 2
Completed N=22
Sildenafil for Treatment of Choroidal Ischemia
Choroidal Ischemia · Vitelliform Macular Dystrophy · Age-Related Macular Degeneration · Central Serous Retinopathy
Source: ClinicalTrials.gov NCT04356716 ↗
Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcomePrimary: Change in Visual Acuity (Sildenafil Group) — 0.00; -0.03 logMAR
Summary
The hypothesis of this study is to determine if there is a benefit afforded by the use of systemic Sildenafil to patients with choroidal and retinal degenerations and dystrophies, such as vitelliform degeneration, dry and reticular age-related macular degeneration (AMD) as well as patients with hereditary and acquired retinal dystrophies such as retinitis pigmentosa and central serous retinopathy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Visual Acuity (Sildenafil Group) |
0.00; -0.03 | — |
| PRIMARY Change in Visual Acuity (Medical Record Review Group) |
0.00; 0.00 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of retinal and choroidal degenerations (reticular or vitelliform AMD or vitelliform-type subretinal drusen) or hereditary or acquired retinal dystrophies (retinitis pigmentosa or central serous retinopathy)
Exclusion Criteria
- Diagnosis of heart disease requiring use of nitrates
- Inability to be examined monthly or bi-monthly
Data sourced from ClinicalTrials.gov (NCT04356716). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.